Pathalys Pharma

Pathalys Pharma is a late-stage clinical biopharmaceutical company with a focus on addressing unmet needs in the management of chronic kidney disease (CKD). Founded in 2021, the company's mission is encapsulated in its slogan: "Our mission is to improve the lives of patients through enhanced therapeutics to advance the management of CKD." Pathalys Pharma operates within the Biopharma and Biotechnology industries, with its headquarters based in the United States. This company is a collaborative effort, being created in partnership with Catalys Pacific and DaVita, aiming to become a multi-asset pharmaceutical company that focuses on the needs of patients with end-stage renal disease. In terms of financing, Pathalys Pharma recently received Debt Financing investment at 18 January 2023, symbolizing a significant milestone in its growth and development. As Pathalys Pharma continues to advance and innovate in the biopharmaceutical space, its partnerships and strategic positioning make it a compelling player to watch in the healthcare industry.